Modification of Serum Brain-Derived Neurotrophic Factor Levels Following Anti-HCV Therapy with Direct Antiviral Agents: A New Marker of Neurocognitive Disorders

Andrea Marino¹, *, Daniele Scuderi¹, Maria Elena Locatelli¹, Adele Gentile¹, Alessio Pampaloni¹, Federica Cosentino¹, Manuela Ceccarelli², Benedetto Maurizio Celesia¹, Francesco Benanti¹, Giuseppe Nunari², Arturo Montineri³ and Bruno Cacopardo¹

¹Section of Infectious Diseases, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Catania, Italy
²Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
³UOC Malattie Infettive, Vittorio Emanuele Hospital, Catania, Italy

*Corresponding author: Section of Infectious Diseases, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Catania, Italy.

Email: andreamarino9103@gmail.com

Received 2019 June 09; Revised 2020 January 01; Accepted 2020 January 19.

Abstract

Background: A large number of central nervous system impairments occur in subjects with chronic HCV infection regardless of liver disease. Brain-derived neurotrophic factor (BDNF) plays an essential role in the adult brain concerning its development and proper functioning. Our study aimed at contributing to the discussion on the involvement of BDNF in neurocognitive disorders associated with HCV infection.

Objectives: We aimed to evaluate the prevalence of neurocognitive disorders in a cohort of HCV-infected subjects, to measure serum BDNF levels in the same cohort according to the degree of neurocognitive disorders, and to evaluate serum BDNF level modification in HCV-infected patients after direct antiviral agents (DAA) therapy.

Methods: We enrolled patients scheduled for DAA therapy in January 2018 from three infectious disease units in Eastern Sicily. Each participant was evaluated for neurocognitive status with MoCA score at baseline and 12 and 24 weeks after the end of therapy. Moreover, we measured serum BDNF levels at baseline and 12 weeks after the end of therapy.

Results: Of 70 HCV-infected patients, 42 (60%) were males. The average age was 57 ± 19 years and the average ALT level was 79 ± 24 UI/mL; 38 (54.3%) individuals had HCV genotype 1 infection and 23 (32.8%) and 25 (35.7%) individuals had F1 and F2 fibrosis stages, respectively. Moreover, 67 (95.7%) individuals achieved sustained virological response. The MoCA score at baseline identified four groups of patients. Higher MoCA scores 24 weeks after the end of therapy highlighted the improvement of neurocognitive status in all groups. Serum BDNF levels in the same four groups, measured 12 weeks after the end of DAA therapy, appeared significantly modified compared to baseline serum BDNF levels, matching the improvement of MoCA score results obtained 24 weeks after DAA therapy.

Conclusions: The serum BDNF level may represent a useful marker of cognitive dysfunction in patients with HCV infection and a useful index for assessing the post-therapy follow-up.

Keywords: Hepatitis C, Brain-Derived Neurotrophic Factor, Direct Antiviral Agents, Neurocognitive Disorders

1. Background

A large number of central nervous system (CNS) impairments, including metabolic, inflammatory, and autoimmune conditions, occur in patients with chronic HCV infection regardless of liver disease (1, 2). Moreover, some reports describe the involvement of the peripheral nervous system and muscular tissue, as well (1, 2). In more detail, neuropsychological and neurocognitive functions are frequently reported as altered in individuals with chronic HCV infection, independently of liver fibrosis and severity of the liver disease. These abnormalities occur both in the absence and in the presence of structural brain damage or signal abnormalities on brain magnetic resonance imaging (3).

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, plays a key role in the adult brain respecting neuronal survival, synaptic plasticity, axonal guidance, cell morphology, memory formation, and...
cognition (4, 5). Brain-derived neurotrophic factor produced in brain neurons acts locally at a synaptic level (6). Variations in circulating BDNF levels may partly reflect its impaired secretion in the brain and reduced brain BDNF levels could be associated with lower circulating BDNF levels (7). The current study aimed at contributing to the discussion on the involvement of BDNF in neurocognitive disorders associated with HCV infection.

2. Objectives

This study aimed (1) to evaluate the prevalence of neurocognitive disorders in a cohort of HCV-infected patients, (2) to measure serum BDNF levels in the same cohort according to the degree of neurocognitive disorders, and (3) to evaluate serum BDNF level modification in HCV-infected patients following direct antiviral agent (DAA) therapy.

3. Methods

We enrolled patients scheduled for DAA therapy in January 2018. The participants were recruited from three infectious disease units in Eastern Sicily, including (1) ARNAS Garibaldi Hospital in Catania, (2) Vittorio Emanuele Hospital in Catania, and (3) Policlinic Gaetano Martino in Messina. All patients underwent DAA treatment between February and June 2018. A post-treatment follow-up was extended in all cases between July and October 2018.

The exclusion criteria included (1) liver cirrhosis with Child-Pugh score B or C and/or liver fibrosis stage 4 (F4, liver stiffness \( \geq 12.5 \)) assessed by hepatic elastography, in order to attenuate any impairment coming from the presence of hepatic encephalopathy, (2) previous neurological disorders of any cause, (3) interferon-based therapies in the previous three years, (4) addiction to illicit drugs or alcohol for at least six months, and (5) concomitant hepatitis B or human immunodeficiency virus infection.

3.1. Measurement of Neurocognitive Status

Neurocognitive status was evaluated at recruitment (baseline), 12, and 24 weeks after the end of DAA therapy. The Montreal cognitive assessment (MoCA) score (8) (0 - 30 points) was used for neurocognitive assessment. Based on the score, neurocognitive status was classified as follows (9):

- From 26 to 30 points: no neurocognitive disorder
- From 19 to 25 points: mild neurocognitive disorder
- From 10 to 18 points: moderate neurocognitive disorder
- From 0 to 9 points: major neurocognitive disorder

3.2. Serum BDNF Measurement

A Human Free BDNF Quantikine ELISA Kit (R&D Systems) was used to measure the serum BDNF levels at baseline and 12 weeks after the end of DAA therapy, with a sensitivity limit of 20 pg/mL and an assay range between 62.5 and 4,000 pg/mL. We measured BDNF in the contest of routine blood sampling.

3.3. Statistical Analysis

Statistical analysis was performed using PRISM software (GraphPad). Serum HCV RNA values were all expressed as UI/mL and logarithmically transformed to normalize their distribution. Data were expressed as means \( \pm \) standard deviation (SD). Categorical variables were analyzed using Fisher’s exact test. Serum BDNF mean values were compared pre- and post-DAA treatment using inter-group analysis with the unpaired Student’s t-test. One-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis was used to compare BDNF levels between multiple groups based on the MoCA neurocognitive classification.

4. Results

Overall, 70 HCV-infected patients were recruited, including 42 males and 28 females. The mean age was 57 \( \pm \) 19 years and the average ALT level was 79 \( \pm \) 24 UI/L. The logarithmic HCV viral load was 5.4 \( \pm \) 1.2 \( \times \) 10^6 UI/mL.

Concerning HCV genotypes, 38 individuals had genotype 1 infection, 11 individuals had genotype 2 infection, and 21 individuals had genotype 3 infection. Hepatic elastography classified 23 individuals as affected with F1 fibrosis, 25 as affected with F2 fibrosis, and 22 as affected with F3 fibrosis (Table 1).

For treatment, 12 subjects took Sofosbuvir/Velpatasvir, 25 took Sofosbuvir/Ledipasvir, 18 took Sofosbuvir/Daclatasvir and 15 took Elbasvir/Grazoprevir. In all cases, DAA therapy was administered for as long as 12 weeks (Table 2).

Twelve weeks after the end of DAA therapy, 67 (95.7%) individuals achieved sustained virological response (SVR 12), whereas three had a virological failure (relapse).

4.1. MoCA Score Evaluation

At baseline, MoCA scores differentiated four groups of patients as follows: (1) 21 (30%) individuals with major neurocognitive problems, (2) 19 (27.1%) individuals with moderate neurocognitive problems, (3) 18 (25.7%) individuals with mild neurocognitive problems, and (4) 12 (17.2%) individuals with no neurocognitive problems. The results of MoCA scores measured 12 and 24 weeks after the end of DAA therapy are shown in Table 3.
Table 1. Characteristics of the Extended Cohort

| Characteristics of the Cohort | Valuesa |
|-----------------------------|---------|
| Male                        | 42 (60) |
| Female                      | 28 (40) |
| Average age (y)             | 57 ± 19 |
| Average ALT levels (UI/L)   | 79 ± 24 |
| Logarithmic HCV-RNA levels (UI/mL) | 5.4 ± 1.2 × 10⁶ |

HCV genotypes

1 38 (54.3)
2 11 (16.2)
3 21 (30)

Hepatic elastography

F1 23 (32.8)
F2 25 (35.7)
F3 22 (31.5)

Values are expressed as mean ± SD or No. (%).

Table 2. Direct Antiviral Agent (DAA) Therapy Administered

| DAA Therapy Administered | Number of Patients, No. (%) |
|--------------------------|----------------------------|
| Sofosbuvir/Velpatasvir   | 12 (17.1)                  |
| Sofosbuvir/Ledipasvir    | 25 (35.7)                  |
| Sofosbuvir/Daclatasvir   | 18 (25.7)                  |
| Elbasvir/Grazoprevir     | 15 (21.5)                  |

Table 3. Number of Subjects in Four Groups Determined by Montreal Cognitive Assessment (MoCA) Scorea

|                  | Baseline | After 12 Weeks | After 24 Weeks |
|------------------|----------|----------------|----------------|
| Major NCD        | 21 (30)  | 20 (28.6)      | 5 (7.2)        |
| Moderate NCD     | 19 (27.1)| 17 (24.2)      | 5 (7.2)        |
| Mild NCD         | 18 (25.7)| 21 (30)        | 44 (62.8)      |
| No NCD           | 12 (17.2)| 12 (17.2)      | 16 (22.8)      |

Abbreviation: NCD, neurocognitive diseases.
aValues are expressed as No. (%).

4.2. Serum BDNF Detection

We measured serum BDNF levels in the four groups previously pinpointed by the MoCA score. The average serum BDNF levels were as follows: (1) 77 ± 11 pg/mL among 21 individuals with major neurocognitive disorders, (2) 122 ± 28 pg/mL among 19 individuals with moderate neurocognitive disorders, (3) 115 ± 28 pg/mL among 18 individuals with mild neurocognitive disorders, and (4) 279 ± 41 pg/mL among 12 individuals with no neurocognitive problems.

Notably, the serum BDNF levels in the first group appeared statistically significantly different from BDNF levels in the fourth group (P < 0.05). The average BDNF level in the four groups, measured 12 weeks after the end of DAA therapy, appeared significantly modified compared to basal BDNF levels. The average serum BDNF levels after SVR 12 are shown in detail in Table 4.

Table 4. Serum Brain-derived Neurotrophic Factor (BDNF) Level Variations in Four Groups From Baseline to SVR 12

|                   | Serum BDNF Levelsa | P Value |
|-------------------|---------------------|---------|
|                   | Baseline | After 12 Weeks |         |
| Major NCD         | 77 ± 11  | 195 ± 71       | < 0.01  |
| Moderate NCD      | 122 ± 28 | 217 ± 69       | < 0.05  |
| Mild NCD          | 115 ± 28 | 202 ± 66       | < 0.05  |
| No NCD            | 279 ± 41 | 285 ± 81       | N.S.    |

aValues are expressed as mean ± SD.

Concerning five patients who still displayed major NCD at 24 weeks after the end of anti-HCV therapy (Table 3), their serum BDNF levels measured 12 weeks after the end of DAA treatment are shown in Table 5.

Table 5. Serum Brain-derived Neurotrophic Factor (BDNF) Levels of Five Patients with Major NCD at 24 Weeks After the End of Therapy

|      | Baseline | After 12 Weeks |
|------|----------|----------------|
| 61   | 64       |
| 70   | 68       |
| 68   | 73       |
| 81   | 78       |
| 76   | 82       |

5. Discussion

Laboratory results, showing the presence of HCV-RNA, NS5A, and NS3 in microglial cells and astrocytes, highlighted the fact that HCV has an independent life cycle in the brain (10). This may explain the significant impairments in executive function and attention and the chronic fatigue reported by HCV patients with normal liver function (3). The HCV associated neurocognitive disorders are unrelated to the stage of liver disease and therefore, the features of this condition are different from those complications observed in individuals with minimal hepatic encephalopathy (HE) (3).

Studies reported impaired levels of metabolites in the basal ganglia of patients with HCV infection and mild liver disease (11) and these alterations were different from abnormalities associated with HE (11). Moreover, neurophys-
iological tests revealed multiple alterations, such as reduced P300 amplitudes and delayed peak latencies, in patients with HCV infection compared to non-infected patients, measuring in this way the subclinical cognitive impairment (12).

This study, like others performed so far (13), documented the impaired CNS function in individuals with chronic HCV infection, independently of the fibrosis stage. Similar results were obtained by Hilsabeck et al. (14), who showed impaired performance in a cohort of patients with chronic HCV, particularly in sustained attention. Other studies have confirmed these findings by documenting the impairment of working memory, sustained attention, and processing speed (15, 16). Forton et al. (17) studied different groups of subjects with chronic HCV infection and found that the HCV-infected group was more impaired than HCV-clear group in neuropsychological tests, independently of the IVDU history. Kramer et al. (12) provided evidence of an association between cognitive impairment and HCV regardless of any history of premorbid substance abuse (18).

Psychiatric diseases such as anxiety, depression, bipolar disorder, post-traumatic stress disorder, and personality disorders are also common in patients with HCV regardless of active or prior psychiatric diseases (19-21). Particularly, all of these conditions may affect the neurocognitive status on measurements of concentration, attention, and processing speed (16). Our findings highlighted a late improvement in cognitive functions in patients who achieved a sustained virological response after DAA therapy, as shown by the MoCA score results.

In the adult brain, BDNF and its specific receptor are heavily expressed. It is involved in growth, differentiation, maturation, and survival of immature neurons, whereas in mature neurons, BDNF plays a key role in synaptic plasticity, augmentation of neurotransmission, and receptor regulation (22). The serum BDNF levels were reported to be significantly lower in patients with advanced dementia than in control subjects (23, 24). The majority of studies have reported reduced BDNF levels in subjects suffering from AD (25) and BDNF seems to be also involved in Parkinson’s disease (4). Moreover, in healthy elderly subjects, higher BDNF serum levels were associated with better neuropsychological status (26, 27).

Concerning immediate and delayed verbal memory and visual memory, BDNF levels were found to be significantly negatively associated with the scores on these functions (28). Moreover, the BDNF serum level was positively correlated with performance on neuropsychological tests investigating executive functioning and attention (29) and it was recognized as a remarkable inhibitor of degeneration, apoptosis-mediated and neurotoxin-induced, of dopaminergic neurons. The BDNF dysfunction may contribute to, or be a consequence of, mental illnesses such as major depressive disorder (30). In the same way, human polymorphisms in the BDNF gene are related to a higher risk of bipolar disorder (4).

Serum BDNF levels measured after 12 weeks from the end of DAA therapy varied according to the MoCA scores measured after 24 weeks from the end of the same therapy. Therefore, BDNF can be an earlier marker of neurocognitive state and it can be used to measure earlier neurocognitive recovery in patients undergoing anti-HCV therapies.

Although not statistically significant, probably because of the small number of subjects involved, serum BDNF levels measured after therapy were also higher in those patients who did not achieve viral eradication. This result shows that the positive effects of antiviral therapy go beyond the simple eradication of the infection, bringing systemic benefits to patients who use it.

5.1. Conclusions

It has been widely demonstrated that the eradication of HCV leads to the reduced progression of liver disease, reduced liver-associated and all-cause-mortality, and reduced extrahepatic manifestations, with a significant improvement in the quality of life (31, 32). Only a few studies have tried to match the serum BDNF levels and neurocognitive disorders in patients with HCV infection (33). Modabernia et al. provided evidence of the association of BDNF with impairment of physical aspects of quality of life in patients with HCV (33) and Lotrich et al. showed that lower BDNF levels before IFN-α therapy were predictive of more serious depression symptoms during therapy with IFN-α (30).

Based on our data, we believe that dosing serum BDNF levels may represent a useful marker of cognitive dysfunction in patients with HCV infection and a useful index for assessing the post-therapy follow-up. Further studies are needed to assess the reliability of serum BDNF levels as a marker of neurocognitive status in HCV-infected patients and its variation after DAA therapy administration.

Footnotes

Authors’ Contribution: Study concept and design: Bruno Cacopardo, Andrea Marino, Francesco Benanti, Giuseppe Nunnari, and Arturo Montineri; acquisition of data: Andrea Marino, Daniele Scuderi, Maria Elena Locatelli, Adele Gentile, Alessio Pampaloni, Federica Cosentino, and Manuela Ceccharelli; analysis and interpretation of data: Bruno Cacopardo, Giuseppe Nunnari, and Arturo Montineri; drafting of the manuscript: Andrea Marino; critical revision of the manuscript for important
Conflict of Interests: The authors declare that they have no conflicts of interest.

Ethical Approval: Blood venipuncture to detect serum BDNF levels was performed in the contest of routine blood sampling for clinical monitoring of patients treated with anti-HCV antivirals, as required by Italian legislation. No extra interventions or clinical procedures were performed on patients for this study. Before MoCA scale administration, informed written consent was collected from each patient as part of a concomitant clinical trial on the prevalence of cognitive disorders in HCV-infected patients.

Funding Support: There was no funding/support.

References

1. Monaco S, Ferrari S, Gajoffato A, Zanuso G, Mariott S. HCV-related nervous system disorders. Clin Dev Immunol. 2012;2012:236418. doi: 10.1155/2012/236418. [PubMed: 22899946]. [PubMed Central: PMC3414089].

2. Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. World J Gastroenterol. 2015;21(8):2269-80. doi: 10.3748/wjg.v21.i8.2269. [PubMed: 25741133]. [PubMed Central: PMC4342902].

3. Monaco S, Mariott S, Ferrari S, Calabrese M, Zanuso G, Gajoffato A, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol. 2015;21(42):9197-83. doi: 10.3748/wjg.v21.i42.9197. [PubMed: 26576086]. [PubMed Central: PMC464119].

4. Balaramasingam S, Janka A. Brain Derived Neurotrophic Factor: A novel neurotrophin involved in psychiatric and neurological disorders. Pharmaco Ther. 2012;134(1):116-24. doi: 10.1016/j.pharmthera.2012.01.006. [PubMed: 22681237].

5. Nettiksimmons J, Simonick EM, Harris T, Satterfield S, Rosano C, Yaffe K, et al. The associations between serum brain-derived neurotrophic factor, potential confounders, and cognitive decline: A longitudinal study. PLoS One. 2014;9(3). e91393. doi: 10.1371/journal.pone.0091393. [PubMed: 24670553]. [PubMed Central: PMC3966784].

6. Partridge WM. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Exp Adv Med Biol. 2002;511:397-430. doi: 10.3007/s1465-0123-7.15. [PubMed: 12575830].

7. Lommatzsch M, Zingler D, Schuhbaech K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2009;31(5):1151-23. doi: 10.1016/j.neurobiolaging.2009.03.002. [PubMed: 1958535].

8. Nasredinne ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2010;58(1):395-9. doi: 10.1111/j.1532-5415.2009.02211.x. [PubMed: 1587019].

9. Nasredinne ZS. MOCA test. 2006. Available from: https://www.mocatest.org/faq/.

10. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat. 2012;19(5):301-6. doi: 10.1111/j.1365-2893.2012.05910.x. [PubMed: 22497808].

11. Forton DM, Allsop M [Main J], Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358(9275):38-9. doi: 10.1016/S0140-6736(00)02707-3. [PubMed: 11445379].

12. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002;37(3):349-54. doi: 10.1053/jhep.2002.38275. [PubMed: 12175630].

13. McAndrews MP, Farncik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41(4):801-8. doi: 10.1002/hep.20835. [PubMed: 15793855].

14. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35(2):440-6. doi: 10.1053/jhep.2002.38275. [PubMed: 11826421].

15. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9(6):847-54. doi: 10.1017/S1355617703960048. [PubMed: 14612243].

16. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41(5):545-51. doi: 10.1016/j.jhep.2004.07.022. [PubMed: 15596659].

17. Forton DM, Thomas HC, Murphy CA, Allsop M, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35(2):439-9. doi: 10.1053/hep.2002.30688. [PubMed: 11826420].

18. Guaraldi CT, Johnson IG, Benedict KB. Neuroregression in depression: Patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci. 2006;18(2):217-25. doi: 10.1016/j.njcn.2005.12.003. [PubMed: 16720799].

19. Wright MM, Kowdley KV, Russo E, Ciechanowski PS, Larson AM, Karon WT. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49(5):317-7. doi: 10.1016/s0022-3999(00)00155-0. [PubMed: 1164055].

20. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123(2):476-82. doi: 10.1016/s0016-5085(01)01331-6. [PubMed: 1214560].

21. Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2002;6(3):535-42. doi: 10.1016/s0168-8278(02)00017-x. [PubMed: 11852691].

22. Numakawa T, Suzuki S, Kuma M, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histopathol. 2001;16(2):237-58. doi: 10.14670/HH-25.237. [PubMed: 20087710].

23. Laske C, Stranks E, Leweke T, Eschweiler GW, Wittorf A, Richartz E, et al. Stage-dependent BDNF serum concentrations in Alzheimer’s disease. J Neural Transm (Vienna). 2006;113(4):321-7. doi: 10.1007/s00702-005-0397-y. [PubMed: 16362629].

24. Schindowski K, Bierkens K, Buey L. Neurotrophic factors in Alzheimer’s disease – Role of axonal transport. Genes Brain Behav. 2008;7 Suppl 1:43-56. doi: 10.1111/j.1601-83X.2007.00178.x. [PubMed: 18184369]. [PubMed Central: PMC228391].

25. Peng S, Wu J, Mufson EJ, Fahnstock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93(6):5342-1. doi: 10.1111/j.1471-4159.2005.03303.x. [PubMed: 15935057].

26. Gunstad J, Benitez A, Smith J, Glickman E, Spitznagel MB, Alexander T, et al. Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J Geriatr Psychiatry

Hepat Mon. 2020;20(2):e95101. 5
27. Driscoll I, Martin B, An Y, Maudsley S, Ferrucci L, Mattson MP, et al. Plasma BDNF is associated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. *PLoS One*. 2012;7(4):e35217. doi: 10.1371/journal.pone.0035217. [PubMed: 22523577]. [PubMed Central: PMC327651].

28. O’Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L, et al. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer’s disease cases. *Dement Geriatr Cogn Disord*. 2013;31(1):31–6. doi: 10.1159/000321980. [PubMed: 21135555]. [PubMed Central: PMC3019366].

29. Costa A, Peppe A, Carlesimo GA, Zabberoni S, Scalici F, Caltagirone C, et al. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson’s disease patients with mild cognitive impairment. *Front Behav Neurosci*. 2015;9:253. doi: 10.3389/fnbeh.2015.00253. [PubMed: 26441580]. [PubMed Central: PMC4569860].

30. Lotrich FE, Albusaysi S, Ferrell RE. Brain-derived neurotrophic factor serum levels and genotype: Association with depression during interferon-alpha treatment. *Neuropsychopharmacology*. 2013;38(6):985–95. doi: 10.1038/npp.2012.263. [PubMed: 23303061]. [PubMed Central: PMC3629388].

31. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. *Gastroenterology*. 2018;155(2):410–421.e4. doi: 10.1053/j.gastro.2018.04.008. [PubMed: 29655836].

32. Malaguarnera M, Motta M, Vacante M, Malaguarnera G, Caraci F, Nunnari G, et al. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. *Am J Transl Res*. 2015;7(11):2510–8. [PubMed: 26807995]. [PubMed Central: PMC4697727].

33. Modabbernia A, Ashrafi M, Keyvani H, Taslimi S, Poorkaveh A, Merat S, et al. Brain-derived neurotrophic factor predicts physical health in untreated patients with hepatitis C. *Biol Psychiatry*. 2011;70(5):e31–2. doi: 10.1016/j.biopsych.2011.01.028. [PubMed: 21429476].